Genis-Mendoza AD, Martínez-Magaña JJ, Bojórquez C, Téllez-Martínez JA, Jiménez-Genchi J, Roche A, Bojorge A, Chávez M, Castañeda C, Guzmán R, Zapata L, Aguilar-Méndez D, Lanzagorta N, Rebolledo I, Castro-Chavira S, Fernández T, Orozco l, Nicolini H, Martínez-Hernández AG

Language: Spanish
References: 24
Page: 555-560
PDF size: 185.49 Kb.

ABSTRACT

Introduction: In Mexico, the prevalence of neurocognitive disorders (NCDs) has increased in parallel with the increase in life expectancy. The E4 allele of the gene that encodes apolipoprotein E (APOE) is the main genetic risk factor for cognitive impairment. Objective: To replicate the association of APOE-E4 allele with neurocognitive impairment in a Mexican population, as well as to implement a genetic risk-detection program with the APOE-E4 allele. Method: A program was structured for the detection of APOE-E4 allele risk in different recruiting centers from the central zone of the Mexican Republic, with three stages: recruitment and selection of candidates for the detection of the risk-allele, genetic risk analysis and delivery of results. Results: In the genetic-association study to replicate the association with neurocognitive disorders by means of multivariate logistic models, the APOE-E4 allele increased the risk for cognitive impairment in the Mexican populations by approximately 6 % (OR: 5.83, p = 0.0025). In addition, 367 genetic risk results were delivered. Conclusions: The present program is the first one to be implemented in Mexico with the purpose to inform on a genetic risk factor for neurocognitive disorders in several centers of the country.

REFERENCES

1. Llibre-Rodríguez JJ, Ferri CP, Acosta D, Guerra M, Huang Y, Jacob KS, et. al. Prevalence of dementia in Latin America, India, and China: a population-based cross-sectional survey. Lancet. 2008;372(9637): 464-474.

2. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9(1):63-75.

3. Mejía-Arango S, Gutiérrez LM. Prevalence and incidence rates of dementia and cognitive impairment no dementia in the Mexican population: data from the Mexican Health and Aging Study. J Aging Health. 2011; 23(7):1050-1074.

4. Stefanacci RG. The costs of Alzheimer’s disease and the value of effective therapies. Am J Manag Care. 2011;17(Suppl13):S356-S362.

5. The Lancet Neurology. Pointing the way to primary prevention of dementia. Lancet Neurol. 2017;16(9):677.

6. Daviglus ML, Bell CC, Berrettini W, Bowen PE, Connolly ES, Cox NJ, et al. NIH state-of-the-science conference statement: preventing Alzheimer’s disease and cognitive decline. NIH Consens State Sci Statements. 2010;27(4):1-30.

7. Barnett JH, Lewis L, Blackwell AD, Taylor M. Early intervention in Alzheimer’s disease: a health economic study of the effects of diagnostic timing. BMC Neurol. 2014;14:101.

8. Panegyres PK, Berry R, Burchell J. Early Dementia Screening. Diagnostics. 2016;6(1) 6.

9. Hampel H, Broich K, Hoessler Y, Pantel J. Biological markers for early detection and pharmacological treatment of Alzheimer’s disease. Dialogues Clin Neurosci. 2009;11(2):141-157.

10. Elias-Sonnenschein LS, Viechtbauer W, Ramakers IH, Verhey FR, Visser PJ. Predictive value of APOE-ε4 allele for progression from MCI to AD-type dementia: a meta-analysis. J Neurol Neurosurg Psychiatry. 2011;82(10):1149-1156.

11. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet. 2007;39(1):17-23.

12. Qian J, Wolters FJ, Beiser A, Haan M, Ikram MA, Karlawish J, et al. APOE-related risk of mild cognitive impairment and dementia for prevention trials: an analysis of four cohorts. PLoS Med. 2017;14(3) e1002254.

13. Gutiérrez-Robledo LM, Arrieta-Cruz I. Dementia in Mexico: the need for a National Alzheimer´s Plan. Gac Med Mex. 2015;151(5) 667-673.

14. Diagnostic and statistical manual of mental disorders. Quinta edición. EE.UU.: American Psychiatric Association; 2013.

15. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.

16. Contreras-Cubas C, Sánchez-Hernández B, García-Ortiz H, Martínez- Hernández A, Barajas-Olmos F, Cid M, et. al. Heterogenous distribution of MTHFR gene variants among mestizos and diverse Amerindian groups from Mexico. PLoS One. 2016;11(9):e0163248.

17. Andermann A, Blancquaert I. Genetic screening: a primer for primary care. Can Fam Physician. 2010;56(4):333-339.

18. Ihle A, Bunce D, Kliegel M. APOE ε4 and cognitive function in early life: a meta-analysis. Neuropsychology. 2012;26(3):267-277.

19. Agarwal R, Tripathi CB. Association of apolipoprotein E genetic variation in Alzheimer’s disease in Indian population: a meta-analysis. Am J Alzheimers Dis Other Demen. 2014;29(7):575-582.

20. Chen K, Sun YM, Zhou Y, Zhao Q, Ding D, Guo Q. Associations between APOE polymorphisms and seven diseases with cognitive impairment including Alzheimer’s disease, frontotemporal dementia, and dementia with Lewy bodies in southeast China. Psychiatr Genet. 2016; 26(3):124-131.

21. Campos M, Edland SD, Peavy GM. An exploratory study of APOE-ε4 genotype and risk of Alzheimer’s disease in Mexican Hispanics. J Am Geriatr Soc. 2013;61(6):1038-1040.

22. Yamazaki Y, Painter MM, Bu G, Kanekiyo T. Apolipoprotein E as a therapeutic target in Alzheimer’s disease: a review of basic research and clinical evidence. CNS Drugs. 2016;30(9):773-789.

23. Maltese PE, Poplavskaia E, Malyutkina I, Sirocco F, Bonizzato A, Capodicasa N, et. al. Genetic tests for low- and middle-income countries: a literature review. Genet Mol Res. 2017;16(1).

24. Ashida S, Koehly LM, Roberts JS, Chen CA, Hiraki S, Green RC. Disclosing the disclosure: factors associated with communicating the results of genetic susceptibility testing for Alzheimer’s disease. J Health Commun. 2009;76814(8):768-784.